Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label adolescent Phase 3 study of Icotrokinra for moderate to severe ulcerative colitis
MOH_2025-10-05_014369Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icotrokinra in autoimmune colitis, sponsored by Johnson & Johnson. Primary endpoint: Clinical remission induction and maintenance. Started Sep 2025; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2025-10-05_014369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-05_014369.